Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats

• Published in: Clinical and experimental immunology Vol. 121; no. 1; pp. 151 - 156
• Main Authors: Sáez‐Torres, I., Espejo, C., Pérez, J. J., Acarín, N., Montalban, X., Martínez‐Cáceres, E. M.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01.07.2000; Blackwell; Oxford University Press; Blackwell Science Inc
• Subjects: Animals; Biological and medical sciences; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental - drug therapy; Encephalomyelitis, Autoimmune, Experimental - immunology; Encephalomyelitis, Autoimmune, Experimental - prevention & control; experimental autoimmune encephalomyelitis; Female; g-Interferon; Guinea Pigs; Interferon-gamma - biosynthesis; Interleukin-4 - biosynthesis; Lewis rat; Medical sciences; multiple sclerosis; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis; Neuroimmunology; Neurology; peptide T; Peptide T - administration & dosage; Peptide T - therapeutic use; Pilot Projects; Rats; Rats, Inbred Lew; Autoimmunity; Animal model; Nervous system diseases; Multiple sclerosis; Encephalomyelitis; Rat; Interleukin; Cytokine; Rodentia; Biological activity; Cerebral disorder; Inflammatory disease; Vertebrata; Octapeptide; Mammalia; Synthetic product; Animal; Central nervous system disease; Spinal cord disease; Gamma interferon

Peptide T has been shown to inhibit T cell activation and cytokine production and function. Moreover, it has been reported to be a safe treatment in humans. We have studied the ability of peptide T to prevent or ameliorate EAE in Lewis rats. Peptide T was administered subcutaneously at different dos...